Bruker (NASDAQ:BRKR) Stock Rating Lowered by Zacks Research

Bruker (NASDAQ:BRKR) was downgraded by equities research analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Wednesday, Zacks reports.

A number of other equities research analysts have also recently weighed in on BRKR. JPMorgan Chase & Co. raised their price target on Bruker from $55.00 to $65.00 and gave the company an “overweight” rating in a report on Monday, June 8th. Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. UBS Group set a $60.00 target price on Bruker in a research note on Wednesday, June 24th. Leerink Partners lifted their price target on Bruker from $60.00 to $70.00 and gave the company an “outperform” rating in a report on Tuesday, July 7th. Finally, Stifel Nicolaus set a $50.00 price target on shares of Bruker in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, five have issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $56.64.

Bruker Price Performance

NASDAQ:BRKR opened at $59.41 on Wednesday. The company has a quick ratio of 0.92, a current ratio of 1.85 and a debt-to-equity ratio of 0.76. The firm has a market cap of $9.05 billion, a PE ratio of -84.87, a price-to-earnings-growth ratio of 1.81 and a beta of 1.26. Bruker has a 12 month low of $28.95 and a 12 month high of $65.30. The company’s 50-day moving average price is $58.81 and its two-hundred day moving average price is $48.57.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Tuesday, August 4th. The medical research company reported $0.49 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.11. Bruker had a negative net margin of 2.35% and a positive return on equity of 12.47%. The company had revenue of $838.50 million during the quarter, compared to analyst estimates of $853.57 million. During the same quarter last year, the business posted $0.32 earnings per share. The company’s revenue was up 5.2% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. On average, equities analysts anticipate that Bruker will post 2.12 EPS for the current fiscal year.

Institutional Investors Weigh In On Bruker

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Los Angeles Capital Management LLC acquired a new position in shares of Bruker during the fourth quarter valued at $26,000. Allworth Financial LP increased its position in Bruker by 40.6% in the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after purchasing an additional 257 shares during the period. Essential Partners LLC acquired a new stake in Bruker in the first quarter worth about $36,000. Global Retirement Partners LLC bought a new stake in Bruker during the 2nd quarter worth about $38,000. Finally, Parallel Advisors LLC raised its holdings in Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.